The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking

Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation

(2010) M Buchwald et al.   LEUKEMIA

Molecular pathogenesis of peripheral neuroblastic tumors

(2010) I Janoueix-Lerosey et al.   ONCOGENE

Anaplastic lymphoma kinase: signalling in development and disease

(2009) Ruth H. Palmer et al.   BIOCHEMICAL JOURNAL

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

(2009) E. Martinelli et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Inhibition of ALK Signaling for Cancer Therapy

(2009) Y. P. Mosse et al.   CLINICAL CANCER RESEARCH

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

(2009) Thomas R Webb et al.   Expert Review of Anticancer Therapy

Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes

(2009) Chunaram Choudhary et al.   MOLECULAR CELL

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

(2008) Helena Carén et al.   BIOCHEMICAL JOURNAL

C. elegans Anaplastic Lymphoma Kinase Ortholog SCD-2 Controls Dauer Formation by Modulating TGF-β Signaling

(2008) David J. Reiner et al.   CURRENT BIOLOGY

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE